Compare · CELZ vs MCO
CELZ vs MCO
Side-by-side comparison of Creative Medical Technology Holdings Inc. (CELZ) and Moody's Corporation (MCO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELZ and MCO operate in Finance: Consumer Services (Finance), so they compete in similar markets.
- MCO is the larger of the two at $77.52B, about 9667.0x CELZ ($8.0M).
- Over the past year, CELZ is down 17.1% and MCO is down 7.5% - MCO leads by 9.6 points.
- MCO has hit the wire 10 times in the past 4 weeks while CELZ has been quiet.
- MCO has more recent analyst coverage (25 ratings vs 1 for CELZ).
- Company
- Creative Medical Technology Holdings Inc.
- Moody's Corporation
- Price
- $2.08-4.59%
- $449.65+1.31%
- Market cap
- $8.0M
- $77.52B
- 1M return
- -6.73%
- -0.39%
- 1Y return
- -17.13%
- -7.52%
- Industry
- Finance: Consumer Services
- Finance: Consumer Services
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 10
- Recent ratings
- 1
- 25
Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona.
Moody's Corporation
Moody's Corporation operates as an integrated risk assessment firm worldwide. It operates in two segments, Moody's Investors Service and Moody's Analytics. The Moody's Investors Service segment publishes credit ratings and provides assessment services on various debt obligations, programs and facilities, and entities that issue such obligations, such as various corporate, financial institution, and governmental obligations; and structured finance securities. This segment provides ratings in approximately 140 countries. Its ratings are disseminated through press releases to the public through electronic media, including the internet and real-time information systems used by securities traders and investors. This segment has rated approximately 5,000 non-financial corporates; 3,600 financial institutions; 16,000 public finance issuers; 145 sovereigns; 47 supranational institutions; 459 sub-sovereigns; and 1,000 infrastructure and project finance issuers, as well as 9,100 structured finance deals. The Moody's Analytics segment develops a range of products and services that support the risk management activities of institutional participants in financial markets; and offers subscription based research, data, and analytical products comprising credit ratings, credit research, quantitative credit scores and other analytical tools, economic research and forecasts, business intelligence and company information products, commercial real estate data and analytical tools, and on-line and classroom-based training services, as well as credentialing and certification services. It also offers software solutions, as well as related risk management services; and offshore analytical and research services with learning solutions and certification programs. The company was formerly known as Dun and Bradstreet Company and changed its name to Moody's Corporation in September 2000. Moody's Corporation was founded in 1900 and is headquartered in New York, New York.
Latest CELZ
- SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
- Amendment: SEC Form 10-K/A filed by Creative Medical Technology Holdings Inc.
- SEC Form 10-K filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
- Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
- Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
Latest MCO
- Director Van Saun Bruce was granted 22 shares, increasing direct ownership by 0.22% to 9,880 units (SEC Form 4)
- Director Forlenza Vincent A was granted 17 shares, increasing direct ownership by 0.19% to 8,763 units (SEC Form 4)
- Director Minaya Jose was granted 7 shares, increasing direct ownership by 0.23% to 2,908 units (SEC Form 4)
- Director Esperdy Therese was granted 12 shares, increasing direct ownership by 0.23% to 5,228 units (SEC Form 4)
- Director Sawicki Lisa P was granted 1 shares, increasing direct ownership by 0.23% to 529 units (SEC Form 4)
- Director Seidman Leslie was granted 18 shares, increasing direct ownership by 0.15% to 12,191 units (SEC Form 4)
- Director Bermudez Jorge A. was granted 20 shares, increasing direct ownership by 0.09% to 22,939 units (SEC Form 4)
- SVP - General Counsel Steele Richard G sold $71,680 worth of shares (158 units at $453.67) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 1,985 units (SEC Form 4)
- President and CEO Fauber Robert sold $665,534 worth of shares (1,467 units at $453.67) as part of a pre-agreed trading plan and exercised 1,167 shares at a strike of $140.03, decreasing direct ownership by 0.57% to 52,564 units (SEC Form 4)
- Moody's to Host Q&A Session on Generative AI Strategy on June 8, 2026